SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Natco Pharma receives FIPB approval to raise Foreign Investment Limit to 31.5%

14 Aug 2015 Evaluate

Natco Pharma has received approval from Foreign Investment Promotion Board (FIPB) for increase of Foreign Investment Limit from 24% to 31.5% of the paid up equity share capital of the company. FIPB has also approved issue and allotment of eligible securities to Qualified Institutional Buyers (QIBs) up to Rs 450 crore.

Natco Pharma was promoted as a private company to be in the business of research, developing, manufacturing and marketing of pharmaceutical substances and finished dosage forms for Indian and International markets.



Natco Pharma Share Price

1103.90 -20.55 (-1.83%)
10-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1654.70
Dr. Reddys Lab 1232.00
Cipla 1229.60
Zydus Lifesciences 915.45
Lupin 2332.70
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×